You're signed outSign in or to get full access.
About
Caroline Stout is a Partner at EcoR1 Capital, a San Francisco-based investment firm specializing in the biotechnology sector. In her current role, she leads investments in innovative biotech companies and contributes to strategic decision-making, focusing on therapeutic innovation and patient-driven discoveries.
Stout's investment expertise centers on the biotechnology and life sciences industries, where she has guided several of EcoR1's significant investments and maintained board seats at companies such as Affinia Therapeutics and Neogene Therapeutics. Before joining EcoR1 in 2014, she worked as an investment banker at Credit Suisse in New York, further deepening her financial and sectoral acumen.
She holds a BA in Economics with Honors, a Pre-Medical concentration, and a Cognitive Science minor from Georgetown University, graduating magna cum laude. Stout's professional achievements include serving as Chief Investment Officer of Panacea Acquisition Corp I and II, highlighting her leadership in biotech-focused SPACs and her impact on advancing the sector through both operational and governance roles.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| EcoR1 Capital, LLC | Partner | Dec 2020 to Present | — |
| EcoR1 Capital, LLC | Principal | Jan 2014 to Aug 2023 | — |
| Affinia Therapeutics | Board Member | May 2021 to Present | — |
| Notch Therapeutics | Board Member | Jan 2021 to Present | — |
| Accent Therapeutics, Inc. | Board Member | Jan 2018 to Present | — |
| Neurogene, Inc. | Board Member | Feb 2019 to Jan 2024 | — |
| EcoR1 Capital, LLC | Principal | Jan 2014 to Aug 2023 | EcoR1 Capital, LLC is a biotech focused investment advisory firm. |
| Affinivax Inc. | Board Observer | Jan 2021 to Jan 2023 | — |
| Neogene Therapeutics | Board Member | Aug 2020 to Jan 2023 | — |
| Panacea Acquisition Corp. II | Chief Investment Officer | Apr 2021 to Apr 2023 | — |
| Panacea Acquisition Corp. | Chief Investment Officer | Jul 2020 to Feb 2021 | — |
| Prevail Therapeutics | Board Member | Mar 2018 to Jun 2019 | — |
Education
The Potomac School
High School Diploma
1998 — 2009
Georgetown University
BA, Economics (Honors), Pre-Med, Cognitive Science
The London School of Economics and Political Science (LSE)
Duke University
Skills & Expertise
Others at Ecor1 Capital, LLC (8)
| Name | Role | Location |
|---|---|---|
 | Principal | San Francisco, CA , United States |
 | Principal | San Francisco, CA , United States |
 | Analyst | San Francisco, CA , United States |
 | Analyst | United States |
 | Analyst | United States |
 | Investment Analyst | San Francisco, CA , United States |
W Whan Lee | Analyst | United States |
 | Research Associate | San Francisco, CA , United States |
Similar Fund Managers
| Name | Role | Fund | Location |
|---|---|---|---|
B Bill Scott | Head Trader | No Street GP LP | San Francisco, CA , United States |
 | Analyst | No Street GP LP | San Francisco, CA , United States |
C Chris Gurne | Analyst | Park Presidio Capital LLC | Los Angeles, CA , United States |
L Lee Krowl | Analyst | Park Presidio Capital LLC | San Francisco, CA , United States |
 | Analyst | Think Investments LP | San Francisco, CA , United States |
A Aileen Huang | Equity Research Analyst | Think Investments LP | San Francisco, CA , United States |
